tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

JOINN Laboratories Reports Significant Profit Recovery in Q1 2025

Story Highlights
JOINN Laboratories Reports Significant Profit Recovery in Q1 2025

Elevate Your Investing Strategy:

JOINN Laboratories (China) Co., Ltd. Class H ( (HK:6127) ) just unveiled an update.

JOINN Laboratories (China) Co., Ltd. released its first quarterly report for 2025, revealing a decrease in revenue by 11.54% compared to the same period last year. Despite this, the company reported a significant improvement in net profit attributable to shareholders, which increased by 115.11%, indicating a recovery from previous losses. The report highlights a decline in net cash flow from operating activities by 45.69%, but an increase in basic and diluted earnings per share by 113.89%. These financial results suggest a positive turnaround in profitability, although challenges in cash flow remain.

More about JOINN Laboratories (China) Co., Ltd. Class H

JOINN Laboratories (China) Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating within the laboratory and research industry. The company is focused on providing laboratory services and research support, with a market presence in China and listed on the Hong Kong Stock Exchange.

YTD Price Performance: 6.95%

Average Trading Volume: 4,551,252

Technical Sentiment Signal: Buy

Current Market Cap: HK$11.61B

For detailed information about 6127 stock, go to TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1